RFA-CA-25-004-Full-Announcement.html

This is a Request for Applications (RFA) from the National Cancer Institute (NCI) seeking proposals for the development and validation of emerging biospecimen science technologies for cancer research under grant number RFA-CA-25-004. The funding supports projects to create tools, devices, assays, and methods for handling cancer-relevant biospecimens, with focus areas including sample preservation, quality assessment, and addressing pre-analytical degradation issues.

The opportunity is open to a wide range of applicants including government entities, educational institutions, tribal organizations, nonprofits, and for-profit businesses. It falls under the NCI's Innovative Molecular Analysis Technologies (IMAT) Program and the Cancer Detection and Diagnosis Research grant program (CFDA 93.394). Projects must demonstrate existing preliminary data showing major feasibility gaps have been overcome, though further development and validation is needed. The technologies should advance cancer biology, detection, diagnosis, treatment, or epidemiology research, including addressing cancer health disparities.